TNFR1 and TNFR2 have opposing effects on cardiac remodeling in heart failure, highlighting the need for receptor-specific approaches in anti-TNF therapies.
Answers are grounded in this paper and cite their sources.
Receptor-specific TNF modulation merits preclinical testing in HF; leaves open translation to human outcomes.
TNFR1 and TNFR2 have disparate and opposing effects on remodeling, hypertrophy, NF-kappaB, inflammation, and apoptosis in HF: TNFR1 exacerbates, whereas TNFR2 ameliorates, these events. However, signaling through both receptors is required to induce diastolic dysfunction and oxidative stress. TNFR-specific effects in HF should be considered when therapeutic anti-TNF strategies are developed.
No takes yet. Share an insight, caveat, or question.
Hamid et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: